. >> chris ceo of sarepta, thank you for coming on. we appreciate it. meg tirrell, we appreciate it as well. >>> let's bring in paul hickey from spoke investment group. paul, why are you being debby downer today, after we've had a pretty big week of earnings? >> i'm not saying don't real too much into it. it was a holiday week. week before easter is traditionally a very strong week for the market, so the average gains of over 1% over the last 25 years, well above that last year, but you know, the last time we were up more than 2% in a week was the week before easter was in 2008. we know how that panned out. just don't get too bullish over it. a gain is a gain, but let's see some follow-through. >> light volume really helps that kind of move. responding quite nicely in relationship to the sell-off for the past month, paul. i'm wondering your thoughts, and whether or not we could see a bounce from there. >> well, you know, as far as individual biotech stocks, it's hard to play. i mean, just look at sarepta, it would a huge move today, but had a huge move

in today's first look: investing in hopes and dreams.look at the surge in sarepta therapeuticals.the stock price exploded on investor's hopes that the fda will side with the dreams of families who want to use the company's experimental drug for myscular dystrophy patients. there are signs the fda will give it fast track priority.the main indexes all advanced for a 5th day. that close for the s&p puts it on its longest winning streak for the year. oil settled at a 7 week high.gold opens at a more than 2 week low.there are reports ford will name its coo, mark fields to be its new ceo.current ceo alan mulally has said he will retire before the end of the year. and on the 44th annual earth day, comes the question - how earth friendly are you?eco- america did a poll. 71 percent of americans say they're concerned about climate change. a higher percentage say humans can reverse the damage.but would you pay more for environmentally friendly products to help do that? in asia 58 percent say yes. only 32 percent in the us and russia would buy such products. things have been hopping and popping

sarepta pharmaceutical, possible news from the fda.this experimental drug for muscular dystrophy. and it's the biggest killer as far as genetic killers, the biggest killer, mostly young men that have what we all grew up with watching, you know, jerry lewis and muscular dystrophy. nothing works for it. . in phase ii trials, there were some that thought it was showing efficacy. and then in november, you can see where it dropped off. it was then where the fda didn't think that the ongoing trials gave enough info for a new application. they've been in talks and the news that came out just today is that they have in discussions with the fda, figured out a way to get an nda, new drug application by the end of 2014. >> wow. >> and there'll be some new trials, but it would be accelerated approval and it's the only drug approval. there was another company with a similar drug that didn't work in clinical trials. that one into the november decision. so they found a way forward, i think, is the news. and it would be good. believe me, there's a lot